Ann: Change of Director's Interest Notice, page-3

1. Three of the most important people at pharmaust each buying parcels within the last week.
2. Two trials underway with multiple patients/canines. The people running and involved with these trials are of upmost quality.
3. Signed an intellectual deal with a Multi-billion dollar Japanese pharma last week.
4. No adverse side affects from PPL-1 to date in either canines or humans.
5. Professor Morris has also taken PPL-1 with no adverse effects (said this at the AGM).
6. Management have a significant stake in the company.
7. Epichem growing revenues with strong goals ahead.

Things look great to me with big things to come as more money from mining stocks is put into biotechs.